Is Sorafenib an Optimal Treatment for Hepatocellular Carcinoma With Macrovascular Invasion or Metastatic Disease?
Xiu‐Ping Zhang, Kang Wang, Wei‐Xing Guo, Zhen‐Hua Chen, Shu‐Qun Cheng – 3 March 2018
New biomarkers for drug‐induced liver injury
James W. Dear – 3 March 2018
Alterations in gut microbial function following liver transplant
Jasmohan S. Bajaj, Genta Kakiyama, I. Jane Cox, Hiroshi Nittono, Hajime Takei, Melanie White, Andrew Fagan, Edith A. Gavis, Douglas M. Heuman, Ho Chong Gilles, Phillip Hylemon, Simon D. Taylor‐Robinson, Cristina Legido‐Quigley, Min Kim, Jin Xu, Roger Williams, Masoumeh Sikaroodi, William M. Pandak, Patrick M. Gillevet – 3 March 2018 – Liver transplantation (LT) improves daily function and ameliorates gut microbial composition. However, the effect of LT on microbial functionality, which can be related to overall patient benefit, is unclear and could affect the post‐LT course.
Reply
Nipun Verma, Akash Singh, Virendra Singh – 3 March 2018
Crosstalk between mesenchymal stem cells and T regulatory cells is crucially important for the attenuation of acute liver injury
Marina Gazdic, Bojana Simovic Markovic, Aleksandar Arsenijevic, Nemanja Jovicic, Aleksandar Acovic, C. Randall Harrell, Crissy Fellabaum, Valentin Djonov, Nebojsa Arsenijevic, Miodrag L. Lukic, Vladislav Volarevic – 3 March 2018 – One of the therapeutic options for the treatment of fulminant hepatitis is repopulation of intrahepatic regulatory cells because their pool is significantly reduced during acute liver failure.
Macrophages come on tap for liver fibrosis therapy
Malcolm R. Alison, Wey‐Ran Lin – 3 March 2018
Low‐dose valganciclovir for cytomegalovirus prophylaxis in intermediate‐risk liver transplantation recipients
Salman Khan, Timothy Sullivan, Mohsin Ali, Dallas Dunn, Gopi Patel, Shirish Huprikar – 3 March 2018 – Liver transplantation recipients (LTRs) who are seropositive for cytomegalovirus (CMV) (recipient seropositive [R+]) are at intermediate risk for CMV disease. A preventative strategy following transplant is considered standard of care. Current guidelines recommend high‐dose valganciclovir (VGCV; 900 mg/day adjusted for renal function) for prophylaxis given limited data on the efficacy and safety of low‐dose VGCV (450 mg/day adjusted for renal function).
Growth factor therapy for decompensated cirrhosis: Much ado about nothing?
Cyriac Abby Philips, Philip Augustine, Sunil Mathew, Gopakumar C Valiathan, Solomon K John – 3 March 2018
Early and late changes in natural killer cells in response to ledipasvir/sofosbuvir treatment
Lucy Golden‐Mason, Rachel H. McMahan, Michael S. Kriss, Alexandra L. Kilgore, Linling Cheng, Rachael J. Dran, Amanda Wieland, Hugo R. Rosen – 1 March 2018 – Chronic hepatitis C virus (HCV) infection is characterized by dysregulated natural killer (NK) cell responses. NKs play a critical role in achieving sustained responses to interferon (IFN)‐α‐based therapy. Rapid sustained HCV‐RNA clearance is now achieved with direct‐acting antivirals (DAAs). Studies of patients receiving first‐wave DAAs suggest NK functional restoration.
Combined Dual‐Kidney Liver Transplantation in the United States: A Review of United Network for Organ Sharing/Organ Procurement and Transplantation Network Data Between 2002 and 2012
Grigoriy Shekhtman, Edmund Huang, Gabriel M. Danovitch, Paul Martin, Suphamai Bunnapradist – 1 March 2018 – In kidney‐alone recipients, dual‐kidney transplantation using “higher‐risk” donor organs has shown outcomes comparable to those of single‐kidney transplantation using extended criteria donor (ECD) organs.